Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)
Status:
Terminated
Trial end date:
2014-09-08
Target enrollment:
Participant gender:
Summary
This clinical trial will study the safety, tolerability, and pharmacodynamics of single doses
of MK-8892 in participants with pulmonary arterial hypertension (PAH). The primary objective
is to estimate the measured peak effect of the highest acutely tolerated (HAT) single oral
dose of MK-8892 on pulmonary vascular resistance (PVR).